Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice A Patterns-of-Care and Outcome Analysis

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung... ORIGINAL ARTICLE Safety and Efficacy of Stereotactic Body   Radiotherapy for Stage I Non–Small-Cell Lung Cancer  in Routine Clinical Practice A Patterns-of-Care and Outcome Analysis Matthias Guckenberger, MD,* Michael Allgäuer, MD,† Steffen Appold, MD,‡ Karin Dieckmann, MD,§ Iris Ernst, MD,║ Ute Ganswindt, MD,¶ Richard Holy, MD,# Ursula Nestle, MD,** Meinhard Nevinny-Stickel, MD,†† Sabine Semrau, MD,‡‡ Florian Sterzing, MD,§§ Andrea Wittig, MD,║║ and Nicolaus Andratschke, MD¶¶ average follow-up of 21 months, 3-year freedom from local progres- Introduction: To evaluate safety and efficacy of stereotactic body sion (FFLP) and overall survival (OS) were 79.6% and 47.1%, respec- radiotherapy (SBRT) for stage I non–small-cell lung cancer (NSCLC) tively. The biological effective dose was the most significant factor in a patterns-of-care and patterns-of-outcome analysis. influencing FFLP and OS: after more than 106 Gy biological effective Methods: The working group “Extracranial Stereotactic dose as planning target volume encompassing dose (N = 164), 3-year Radiotherapy” of the German Society for Radiation Oncology per- FFLP and OS were 92.5% and 62.2%, respectively. No evidence of a formed a retrospective multicenter analysis of practice and outcome learning curve or improvement of results with larger SBRT experience after SBRT for stage I NSCLC. Sixteen German and Austrian centers and implementation of new radiotherapy technologies was observed. with experience in pulmonary SBRT were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice A Patterns-of-Care and Outcome Analysis

Journal of Thoracic Oncology , Volume 8 (8) – Aug 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/safety-and-efficacy-of-stereotactic-body-radiotherapy-for-stage-i-non-ADgOd32bNf

References (35)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318293dc45
pmid
23817193
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Safety and Efficacy of Stereotactic Body   Radiotherapy for Stage I Non–Small-Cell Lung Cancer  in Routine Clinical Practice A Patterns-of-Care and Outcome Analysis Matthias Guckenberger, MD,* Michael Allgäuer, MD,† Steffen Appold, MD,‡ Karin Dieckmann, MD,§ Iris Ernst, MD,║ Ute Ganswindt, MD,¶ Richard Holy, MD,# Ursula Nestle, MD,** Meinhard Nevinny-Stickel, MD,†† Sabine Semrau, MD,‡‡ Florian Sterzing, MD,§§ Andrea Wittig, MD,║║ and Nicolaus Andratschke, MD¶¶ average follow-up of 21 months, 3-year freedom from local progres- Introduction: To evaluate safety and efficacy of stereotactic body sion (FFLP) and overall survival (OS) were 79.6% and 47.1%, respec- radiotherapy (SBRT) for stage I non–small-cell lung cancer (NSCLC) tively. The biological effective dose was the most significant factor in a patterns-of-care and patterns-of-outcome analysis. influencing FFLP and OS: after more than 106 Gy biological effective Methods: The working group “Extracranial Stereotactic dose as planning target volume encompassing dose (N = 164), 3-year Radiotherapy” of the German Society for Radiation Oncology per- FFLP and OS were 92.5% and 62.2%, respectively. No evidence of a formed a retrospective multicenter analysis of practice and outcome learning curve or improvement of results with larger SBRT experience after SBRT for stage I NSCLC. Sixteen German and Austrian centers and implementation of new radiotherapy technologies was observed. with experience in pulmonary SBRT were

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Aug 1, 2013

There are no references for this article.